Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 269-279 , June 2006

Familial leukemia

  • Kathleen F. Benson, PhD (Acting Research Assistant Professor)
    • ,
  • Marshall Horwitz, MD, PhD (Associate Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 206 616 4566; fax: +1 206 897 1775.

References 

  1. Merg A, Lynch HT, Lynch JF, Howe JR. Hereditary colon cancer—part I. Curr Probl Surg. 2005;42:195–256
  2. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4:665–676
  3. Nupponen NN, Wallen MJ, Ponciano D, et al. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer. Genes Chromosomes Cancer. 2004;39:119–125
  4. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31:55–59
  5. Shaag A, Walsh T, Renbaum P, et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the ashkenazi jewish population. Hum Mol Genet. 2005;14:555–563
  6. Ferrando AA, Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol. 2000;37:381–395
  7. Segel GB, Lichtman MA. Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells Mol Dis. 2004;32:246–261
  8. Horwitz M. Hematologic cancer. In:  King RA,  Rotter JI,  Motulsky AG editor. The Genetic Basis of Common Disease. New York: Oxford University Press; 2002;p. 749–776
  9. Gale RP, Cozen W, Goodman MT, et al. Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles county. Leuk Res. 2000;24:665–669
  10. Otero JC, Santillana S, Fereyros G. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996;88:377
  11. Tomas JF, Fernandez-Ranada JM. About the increased frequency of acute promyelocytic leukemia among Latinos: the experience from a center in Spain. Blood. 1996;88:2357–2358
  12. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood. 2003;102:2321–2333
  13. Kerber RA, O'Brien E. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer. 2005;103:1906–1915
  14. Caporaso N, Marti GE, Goldin L. Perspectives on familial chronic lymphocytic leukemia: genes and the environment. Semin Hematol. 2004;41:201–206
  15. Goldin LR, Ishibe N, Sgambati M, et al. A genome scan of 18 families with chronic lymphocytic leukaemia. Br J Haematol. 2003;121:866–873
  16. Calin GA, Trapasso F, Shimizu M, et al. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med. 2005;352:1667–1676
  17. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351:2403–2407
  18. Leroy H, Roumier C, Huyghe P, et al. CEBPA point mutations in hematological malignancies. Leukemia. 2005;19:329–334
  19. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166–175
  20. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23:4284–4296
  21. Sellick GS, Pritchard-Jones K, Shepherd V, et al. Loci other than 21q22.12 (RUNX1) and 16q21-23.2 cause familial AML. Leukemia. 2005;19:465–466
  22. Horwitz M, Benson KF, Li FQ, et al. Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21-23.2. Am J Hum Genet. 1997;61:873–881
  23. Horwitz M, Goode EL, Jarvik GP. Anticipation in familial leukemia. Am J Hum Genet. 1996;59:990–998
  24. McInnis MG. Anticipation: an old idea in new genes. Am J Hum Genet. 1996;59:973–979
  25. Daugherty SE, Pfeiffer RM, Mellemkjaer L, et al. No evidence for anticipation in lymphoproliferative tumors in population-based samples. Cancer Epidemiol Biomarkers Prev. 2005;14:1245–1250
  26. Vulliamy T, Marrone A, Szydlo R, et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004;36:447–449
  27. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352:1413–1424
  28. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5:11–20
  29. Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet. 2000;24:266–270
  30. Ge Y, Stout ML, Tatman DA, et al. GATA1, cytidine deaminase, and the high cure rate of down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst. 2005;97:226–231
  31. Li Z, Godinho FJ, Klusmann JH, et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613–619
  32. Shen JJ, Williams BJ, Zipursky A, et al. Cytogenetic and molecular studies of down syndrome individuals with leukemia. Am J Hum Genet. 1995;56:915–925
  33. Niikawa N, Deng HX, Abe K, et al. Possible mapping of the gene for transient myeloproliferative syndrome at 21q11.2. Hum Genet. 1991;87:561–566
  34. Iselius L, Jacobs P, Morton N. Leukaemia and transient leukaemia in Down syndrome. Hum Genet. 1990;85:477–485
  35. Alter BP. Bone marrow failure syndromes in children. Pediatr Clin North Am. 2002;49:973–988
  36. Horwitz M, Li FQ, Albani D, et al. Leukemia in severe congenital neutropenia: defective proteolysis suggests new pathways to malignancy and opportunities for therapy. Cancer Invest. 2003;21:579–587
  37. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the severe chronic neutropenia international registry. Am J Hematol. 2003;72:82–93
  38. van de Geijn GJ, Aarts LH, Erkeland SJ, et al. Granulocyte colony-stimulating factor and its receptor in normal hematopoietic cell development and myeloid disease. Rev Physiol Biochem Pharmacol. 2003;149:53–71
  39. Donadieu J, Leblanc T, Bader MB, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French severe chronic neutropenia study group. Haematologica. 2005;90:45–53
  40. Bellanne-Chantelot C, Clauin S, Leblanc T, et al. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood. 2004;103:4119–4125
  41. Horwitz M, Benson KF, Person RE, et al. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet. 1999;23:433–436
  42. Thompson D, Antoniou AC, Jenkins M, et al. Two ATM variants and breast cancer risk. Hum Mutat. 2005;25:594–595
  43. Gruber SB, Ellis NA, Scott KK, et al. BLM heterozygosity and the risk of colorectal cancer. Science. 2002;297:2013
  44. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606–609
  45. Wang X, D'Andrea AD. The interplay of Fanconi anemia proteins in the DNA damage response. DNA Repair Amst. 2004;3:1063–1069
  46. Morgan GJ, Smith MT. Metabolic enzyme polymorphisms and susceptibility to acute leukemia in adults. Am J Pharmacogenomics. 2002;2:79–92

PII: S1521-6926(05)00105-2

doi: 10.1016/j.beha.2005.11.002

Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 269-279 , June 2006

Article Tools

* Image Usage & Resolution